Outcomes of testing for KRAS exon 2 in the physician survey study.

CI, confidence interval; mCRC, metastatic colorectal cancer.aOne oncologist responded that KRAS testing was not appropriate (Round 1), and one oncologist did not respond (Round 2).bTwo oncologists responded for treatment of patients with mutant mCRC KRAS tumors (one in each round), and one gave an invalid multiple response (Round 1).cSix oncologists were unaware of patients’ tumor KRAS status prior to initiation of panitumumab treatment (Round 1), and one oncologist gave a missing response (Round 2).dFifteen oncologists had administered panitumumab to mCRC patients with mutant KRAS tumors or with tumor KRAS status unknown (seven in Round 1 and eight in Round 2), two oncologists gave a not sure response (Round 2), and one oncologist did not give a response (Round 2).eTen oncologists had administered panitumumab with concurrent oxaliplatin-containing chemotherapy to mCRC patients with mutant KRAS tumors or with tumor KRAS status unknown (three in Round 1 and seven in Round 2), and one oncologist gave a not sure response (Round 1).Outcomes of testing for KRAS exon 2 in the physician survey study.